The Salt Lake Tribune is reporting that public employees in the state of Utah could be paid by their insurance plan to fill prescriptions for high-cost drugs in Mexico instead of in their local pharmacies.
The Salt Lake Tribune is reporting that public employees in the state of Utah could be paid by their insurance plan to fill prescriptions for high-cost drugs in Mexico instead of in their local pharmacies.
PEHP Health and Benefits, a division of Utah Retirement Systems, is a nonprofit trust that provides health benefits to Utah’s public employees, including county, city, school, and other public workers.
According to PEHP’s members’ website, the Pharmacy Tourism Program allows members who are not enrolled in Medicare the option to fill select drugs in Tijuana, Mexico, rather than in their local pharmacies. For members with certain plan types, medications are covered by the payer’s pharmacy benefit at no extra cost, and members are allowed to fill a 90-day supply.
The payer also arranges and pays for roundtrip airfare from Utah to San Diego, California, as well as car transportation across the US—Mexico border to a facility in Tijuana that will dispense the drugs. Finally, patients who take the option to travel to Mexico are also paid a cash reward of $500.
Among the drugs that qualify for the tourism program plan are biologics etanercept (Enbrel), adalimumab (Humira), abatacept (Orencia), and ustekinumab (Stelara). Notably, potentially cost-saving biosimilars for etanercept and adalimumab have been approved by the FDA, but none of the biosimilar options have launched because of patent protection for the originator products.
Other drugs that qualify for the plan are products that treat multiple sclerosis (including glatiramer acetate, dimethyl fumarate, fingolimod, interferon, and teriflunomide) as well as therapies to treat psoriasis (apremilast), osteoporosis (teriparatide) and cancer (abiraterone).
According to the Tribune, state representative Norman Thurston, a Republican representing Provo, said of the plan, “Why wouldn’t we pay $300 to go to San Diego, drive across to Mexico and save the system tens of thousands of dollars? If it can be done safely, we should be all over that.”
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Future of Biosimilar Gene Therapies: Key Issues and Potential
September 11th 2024While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, manufacturing, intellectual property, and market size pose challenges to their development and market entry.
BioRationality: FDA Clarification Provides New Indications and Process Change for Biosimilars
September 9th 2024Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes for reporting modifications, comparability assessments, and the potential for biosimilars to introduce new indications or formulation changes, which could significantly impact their market competitiveness and accessibility.